Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Sesen Bio Stock Got Slammed Today

TheMotleyFool

0 0

Sesen Bio (NASDAQ: SESN) wasn't a very healthy stock on Thursday. The biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. This followed an update on the company's only pipeline drug.

That drug is vicineum, for which Sesen Bio was seeking regulatory approval for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). On Wednesday, the company held a Clinical Type A meeting with the regulator to determine a new path forward for vicineum.

Image source: Getty Images.

Source Fool.com

Like: 0

SESN

Share